Logo image of KIN.BR

KINEPOLIS (KIN.BR) Stock Fundamental Analysis

EBR:KIN - Euronext Brussels - BE0974274061 - Common Stock - Currency: EUR

33.65  -0.45 (-1.32%)

Fundamental Rating

4

Taking everything into account, KIN scores 4 out of 10 in our fundamental rating. KIN was compared to 40 industry peers in the Entertainment industry. There are concerns on the financial health of KIN while its profitability can be described as average. KIN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

KIN had positive earnings in the past year.
KIN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KIN reported negative net income in multiple years.
Of the past 5 years KIN 4 years had a positive operating cash flow.
KIN.BR Yearly Net Income VS EBIT VS OCF VS FCFKIN.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

Looking at the Return On Assets, with a value of 3.20%, KIN is in the better half of the industry, outperforming 67.50% of the companies in the same industry.
KIN's Return On Equity of 19.41% is fine compared to the rest of the industry. KIN outperforms 72.50% of its industry peers.
KIN has a better Return On Invested Capital (6.48%) than 75.00% of its industry peers.
Industry RankSector Rank
ROA 3.2%
ROE 19.41%
ROIC 6.48%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KIN.BR Yearly ROA, ROE, ROICKIN.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

1.3 Margins

Looking at the Profit Margin, with a value of 6.29%, KIN is in the better half of the industry, outperforming 67.50% of the companies in the same industry.
KIN's Profit Margin has been stable in the last couple of years.
KIN has a better Operating Margin (13.74%) than 85.00% of its industry peers.
KIN's Operating Margin has been stable in the last couple of years.
With a Gross Margin value of 23.56%, KIN is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of KIN has remained more or less at the same level.
Industry RankSector Rank
OM 13.74%
PM (TTM) 6.29%
GM 23.56%
OM growth 3YN/A
OM growth 5Y0.72%
PM growth 3YN/A
PM growth 5Y-1.43%
GM growth 3YN/A
GM growth 5Y-0.65%
KIN.BR Yearly Profit, Operating, Gross MarginsKIN.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KIN is destroying value.
There is no outstanding debt for KIN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KIN.BR Yearly Shares OutstandingKIN.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
KIN.BR Yearly Total Debt VS Total AssetsKIN.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B

2.2 Solvency

KIN has an Altman-Z score of 1.45. This is a bad value and indicates that KIN is not financially healthy and even has some risk of bankruptcy.
KIN has a Altman-Z score of 1.45. This is in the better half of the industry: KIN outperforms 65.00% of its industry peers.
The Debt to FCF ratio of KIN is 7.71, which is on the high side as it means it would take KIN, 7.71 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of KIN (7.71) is better than 65.00% of its industry peers.
KIN has a Debt/Equity ratio of 3.70. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of KIN (3.70) is worse than 65.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.7
Debt/FCF 7.71
Altman-Z 1.45
ROIC/WACC0.97
WACC6.65%
KIN.BR Yearly LT Debt VS Equity VS FCFKIN.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

KIN has a Current Ratio of 0.46. This is a bad value and indicates that KIN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.46, KIN is doing worse than 80.00% of the companies in the same industry.
KIN has a Quick Ratio of 0.46. This is a bad value and indicates that KIN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.43, KIN is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.43
KIN.BR Yearly Current Assets VS Current LiabilitesKIN.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

4

3. Growth

3.1 Past

KIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.42%.
The Earnings Per Share has been growing slightly by 3.01% on average over the past years.
The Revenue has been growing slightly by 1.05% in the past year.
Measured over the past years, KIN shows a small growth in Revenue. The Revenue has been growing by 4.93% on average per year.
EPS 1Y (TTM)-11.42%
EPS 3YN/A
EPS 5Y3.01%
EPS Q2Q%-99.42%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y50.88%
Revenue growth 5Y4.93%
Sales Q2Q%-14.89%

3.2 Future

Based on estimates for the next years, KIN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.04% on average per year.
Based on estimates for the next years, KIN will show a small growth in Revenue. The Revenue will grow by 2.49% on average per year.
EPS Next Y-18.47%
EPS Next 2Y10.07%
EPS Next 3Y12.19%
EPS Next 5Y17.04%
Revenue Next Year-4.56%
Revenue Next 2Y1.75%
Revenue Next 3Y3.09%
Revenue Next 5Y2.49%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
KIN.BR Yearly Revenue VS EstimatesKIN.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KIN.BR Yearly EPS VS EstimatesKIN.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 26.50, KIN can be considered very expensive at the moment.
Based on the Price/Earnings ratio, KIN is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
KIN's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.07.
KIN is valuated correctly with a Price/Forward Earnings ratio of 13.51.
80.00% of the companies in the same industry are more expensive than KIN, based on the Price/Forward Earnings ratio.
KIN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.5
Fwd PE 13.51
KIN.BR Price Earnings VS Forward Price EarningsKIN.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

KIN's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, KIN is valued cheaper than 82.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.88
EV/EBITDA 10.53
KIN.BR Per share dataKIN.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A more expensive valuation may be justified as KIN's earnings are expected to grow with 12.19% in the coming years.
PEG (NY)N/A
PEG (5Y)8.79
EPS Next 2Y10.07%
EPS Next 3Y12.19%

4

5. Dividend

5.1 Amount

KIN has a Yearly Dividend Yield of 1.14%.
KIN's Dividend Yield is rather good when compared to the industry average which is at 2.00. KIN pays more dividend than 82.50% of the companies in the same industry.
With a Dividend Yield of 1.14, KIN pays less dividend than the S&P500 average, which is at 2.39.
Industry RankSector Rank
Dividend Yield 1.14%

5.2 History

On average, the dividend of KIN grows each year by 20.78%, which is quite nice.
Dividend Growth(5Y)20.78%
Div Incr Years1
Div Non Decr Years1
KIN.BR Yearly Dividends per shareKIN.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

KIN pays out 41.54% of its income as dividend. This is a bit on the high side, but may be sustainable.
KIN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP41.54%
EPS Next 2Y10.07%
EPS Next 3Y12.19%
KIN.BR Yearly Income VS Free CF VS DividendKIN.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M
KIN.BR Dividend Payout.KIN.BR Dividend Payout, showing the Payout Ratio.KIN.BR Dividend Payout.PayoutRetained Earnings

KINEPOLIS

EBR:KIN (3/26/2025, 5:29:54 PM)

33.65

-0.45 (-1.32%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)08-21 2025-08-21
Inst Owners19.91%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner ChangeN/A
Market Cap921.00M
Analysts86
Price Target51.68 (53.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.14%
Yearly Dividend0.92
Dividend Growth(5Y)20.78%
DP41.54%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.12%
PT rev (3m)-3.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-12.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.39%
Valuation
Industry RankSector Rank
PE 26.5
Fwd PE 13.51
P/S 1.64
P/FCF 8.88
P/OCF 6.56
P/B 5.05
P/tB N/A
EV/EBITDA 10.53
EPS(TTM)1.27
EY3.77%
EPS(NY)2.49
Fwd EY7.4%
FCF(TTM)3.79
FCFY11.26%
OCF(TTM)5.13
OCFY15.25%
SpS20.57
BVpS6.67
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)8.79
Profitability
Industry RankSector Rank
ROA 3.2%
ROE 19.41%
ROCE 8.81%
ROIC 6.48%
ROICexc 6.85%
ROICexgc 8.83%
OM 13.74%
PM (TTM) 6.29%
GM 23.56%
FCFM 18.41%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y0.72%
PM growth 3YN/A
PM growth 5Y-1.43%
GM growth 3YN/A
GM growth 5Y-0.65%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 3.7
Debt/FCF 7.71
Debt/EBITDA 4.22
Cap/Depr 44.37%
Cap/Sales 6.53%
Interest Coverage 3.01
Cash Conversion 87.68%
Profit Quality 292.73%
Current Ratio 0.46
Quick Ratio 0.43
Altman-Z 1.45
F-Score7
WACC6.65%
ROIC/WACC0.97
Cap/Depr(3y)32.78%
Cap/Depr(5y)48.64%
Cap/Sales(3y)5.97%
Cap/Sales(5y)10.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.42%
EPS 3YN/A
EPS 5Y3.01%
EPS Q2Q%-99.42%
EPS Next Y-18.47%
EPS Next 2Y10.07%
EPS Next 3Y12.19%
EPS Next 5Y17.04%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y50.88%
Revenue growth 5Y4.93%
Sales Q2Q%-14.89%
Revenue Next Year-4.56%
Revenue Next 2Y1.75%
Revenue Next 3Y3.09%
Revenue Next 5Y2.49%
EBIT growth 1Y-6.93%
EBIT growth 3YN/A
EBIT growth 5Y5.69%
EBIT Next Year81.02%
EBIT Next 3Y30.65%
EBIT Next 5Y18.22%
FCF growth 1Y-22.26%
FCF growth 3YN/A
FCF growth 5Y31.8%
OCF growth 1Y-6.25%
OCF growth 3YN/A
OCF growth 5Y11.17%